Lemaitre Vascular earnings release, August 4, 2026

Lemaitre Vascular Inc (LMAT) · Form 8-K, Item 2.02 · Filed · SEC filing

LeMaitre Q2 2026 Financial Results

BURLINGTON, MA, August 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.

Q2 2026:

Artegraft sales increased 34% in the quarter. Grafts (+23%), carotid shunts (+18%), and patches (+4%) each posted records, as did EMEA (+18%), APAC (+18%) and the Americas (+5%). Catheters were down 11% in the quarter due to recall-driven overstocking in Q2 2025. Q2 organic growth was 12% excluding catheters.

Gross margin of 72.1% was up 210 bps due to higher prices, mix shift, and operational efficiencies. Operating income of $20.4mm (+26%) also benefited from headcount restraint: 660 at 6/30/2026 vs. 658 at 6/30/2025.

Chairman/CEO George LeMaitre said, “Our focus on the Artegraft international launch paid off in Q2. The product is now approved in 56 countries, accounting for 21% of sales. So our largest product is now our fastest-growing product. To underpin the Artegraft launch and pave the way for RFA, we continue to build our sales force, go direct in new countries and we’re now undertaking six international warehouse expansions. $376m of cash provides strategic optionality.”

Business Outlook

Quarterly Dividend

On July 28, 2026, the

Company’s Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on September 3, 2026, to stockholders of record on August 20, 2026.

Share Repurchase Program

On February 19, 2026, the

Company’s Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company’s website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company’s website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than

200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit www.lemaitre.com.

Use of

Non-GAAP

Financial Measures

LeMaitre management believes that in order to better understand the Company’s short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP.

Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations.

Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. Additionally, the Company has provided percentages for operating income and EPS guidance adjusted to exclude the effects of the employee retention tax credit received in 2025. Management believes that viewing projected growth in operating income and EPS excluding those effects provides an alternative and meaningful view of the Company’s projected profitability.

Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to

Non-GAAP

Financial Measures” below.

Financial statements

Income Statement

For the three months ended — (unaudited) (in thousands)

For the three months ended – June 30, 2026For the three months ended – June 30, 2025For the six months ended – June 30, 2026For the six months ended – June 30, 2025
Net sales70,38264,232136,933124,103
Cost of sales19,61819,25837,77337,709
Gross profit50,76444,97499,16086,394
Operating expenses:Sales and marketing14,40814,89528,92329,107
Operating expenses:General and administrative11,11010,39623,15620,883
Operating expenses:Research and development4,8473,5418,9077,636
Operating expenses:Total operating expenses30,36528,83260,98657,626
Operating expenses:Income from operations20,39916,14238,17428,768
Other income (expense):Investment income3,3862,9806,7105,883
Other income (expense):Interest expense-1,302-1,299-2,602-2,589
Other income (expense):Other income (loss), net-294247-421249
Other income (expense):Income before income taxes22,18918,07041,86132,311
Other income (expense):Provision for income taxes5,1394,2919,1327,521
Other income (expense):Net income17,05013,77932,72924,790
Earnings per share of common stockBasic0.750.611.431.1
Earnings per share of common stockDiluted0.740.61.421.08
Weighted - average shares outstanding:Basic22,85822,61422,83022,592
Weighted - average shares outstanding:Diluted24,53122,89224,50522,896
Weighted - average shares outstanding:Cash dividends declared per common share0.250.20.50.4

Income Statement

For the three months ended — (unaudited) (in thousands)

For the three months ended – June 30, 2026For the three months ended – June 30, 2025For the six months ended – June 30, 2026For the six months ended – June 30, 2025
Reconciliation between GAAP and Non-GAAP Adjusted EBITDANet income as reported17,05013,77932,72924,790
Reconciliation between GAAP and Non-GAAP Adjusted EBITDAInterest (income) expense, net-2,084-1,681-4,108-3,294
Reconciliation between GAAP and Non-GAAP Adjusted EBITDAAmortization and depreciation expense2,6622,6485,2855,200
Reconciliation between GAAP and Non-GAAP Adjusted EBITDAProvision for income taxes5,1394,2919,1327,521
Reconciliation between GAAP and Non-GAAP Adjusted EBITDAAdjusted EBITDA22,76719,03743,03834,217
Reconciliation between GAAP and Non-GAAP Adjusted EBITDAAdjusted EBITDA percentage increase20.0%26.0%

Income Statement

(unaudited) (in thousands)

For the three months ending September 30, 2026Operating income per guidance (midpoint)18,100
For the three months ending September 30, 2026Projected operating income18,100
For the three months ended September 30, 2025Operating income as reported20,312
For the three months ended September 30, 2025Impact of employee retention credit-3,380
For the three months ended September 30, 2025Adjusted operating income16,932
For the three months ended September 30, 2025Adjusted projected operating income increase for the three months ending September 30, 20261,168
For the year ending December 31, 2026Operating income per guidance (midpoint)76,800
For the year ending December 31, 2026Projected operating income76,800
For the year ended December 31, 2025Operating income as reported67,912
For the year ended December 31, 2025Impact of employee retention credit-3,380
For the year ended December 31, 2025Adjusted operating income64,532
For the year ended December 31, 2025Adjusted projected operating income increase for the year ending December 31, 202612,268
For the three months ending September 30, 2026Earnings per share per guidance (midpoint)0.69
For the three months ending September 30, 2026Projected earnings per share0.69
For the three months ended September 30, 2025Earnings per share as reported0.75
For the three months ended September 30, 2025Impact of employee retention credit-0.13
For the three months ended September 30, 2025Adjusted earnings per share0.62
For the three months ended September 30, 2025Adjusted projected earnings per share increase for the three months ending September 30, 20260.07
For the year ending December 31, 2026Earnings per share per guidance (midpoint)2.89
For the year ending December 31, 2026Projected earnings per share2.89
For the year ended December 31, 2025Earnings per share as reported2.52
For the year ended December 31, 2025Impact of employee retention credit-0.14
For the year ended December 31, 2025Adjusted earnings per share2.38
For the year ended December 31, 2025Adjusted projected earnings per share increase for the year ending December 31, 20260.51

Balance Sheet

June 30, 2026 — (amounts in thousands)

June 30, 2026 – (unaudited)December 31, 2025
Current assets:Cash and cash equivalents26,62528,244
Current assets:Short-term marketable securities349,615330,876
Current assets:Accounts receivable, net35,68233,610
Current assets:Inventory and other deferred costs70,50370,422
Current assets:Prepaid expenses and other current assets5,8725,080
Current assets:Total current assets488,297468,232
Current assets:Property and equipment, net29,59126,997
Current assets:Right-of-use leased assets19,99815,762
Current assets:Goodwill65,94565,945
Current assets:Other intangibles, net30,54433,089
Current assets:Deferred tax assets734759
Current assets:Other assets5,4404,906
Current assets:Total assets640,549615,690
Current liabilities:Accounts payable3,2363,646

Cash Flow

For the six months ended — (unaudited) (in thousands)

For the six months ended – June 30, 2026For the six months ended – June 30, 2025
Operating activitiesNet income32,72924,790
Adjustments to reconcile net income to net cash provided by operating activitiesDepreciation and amortization5,2855,200
Adjustments to reconcile net income to net cash provided by operating activitiesStock-based compensation4,0273,990
Adjustments to reconcile net income to net cash provided by operating activitiesAmortization of issuance costs on convertible notes446433
Adjustments to reconcile net income to net cash provided by operating activitiesNon-cash investment income-805
Adjustments to reconcile net income to net cash provided by operating activitiesProvision for inventory write-downs1,5481,030
Adjustments to reconcile net income to net cash provided by operating activitiesProvision for credit losses333337
Adjustments to reconcile net income to net cash provided by operating activitiesForeign currency transaction effect on income145-279
Changes in operating assets and liabilities:Accounts receivables-2,877-5,299
Changes in operating assets and liabilities:Inventory and other deferred costs-1,935-3,454
Changes in operating assets and liabilities:Prepaid expenses and other assets-1,3631,676
Changes in operating assets and liabilities:Accounts payable and other liabilities-6,475-1,250
Changes in operating assets and liabilities:Accrued interest2,156
Changes in operating assets and liabilities:Net cash provided by operating activities31,05829,330
Investing activitiesPurchases of short-term marketable securities-231,434-17,849
Investing activitiesPurchases of property and equipment-5,096-2,725
Investing activitiesPayments related to acquisitions, net of cash acquired-158-95
Investing activitiesProceeds from short-term marketable securities212,489
Investing activitiesNet cash used in investing activities-24,199-20,669
Financing activitiesProceeds from stock option exercises3,7283,072
Financing activitiesDeferred payments for acquisitions-95-1,433
Financing activitiesPayment of withholding taxes in connection with net settlement of equity awards-477-605
Financing activitiesCommon stock cash dividend paid-11,427-9,037
Financing activitiesNet cash used in financing activities-8,271-8,003
Financing activitiesEffect of exchange rate changes on cash and cash equivalents-207909
Financing activitiesNet (decrease) increase in cash and cash equivalents-1,6191,567
Financing activitiesCash and cash equivalents at beginning of period28,24425,610
Financing activitiesCash and cash equivalents at end of period26,62527,177
Full release

Forward-Looking Statements

The Company’s current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.... (truncated)-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, our ability to maintain historic levels of profit growth; our ability to increase the selling prices of our products; the status of our regulatory approvals, compliance with regulatory requirements, and the potential for adverse regulatory findings or enforcement actions arising from inspections, audits, or other regulatory reviews, affecting our ability to market and sell our products domestically and internationally; competition from other medical device companies and alternative medical technologies; our ability to source, acquire, and integrate acquisitions; our dependence on sole- or limited-source suppliers; our ability to engage sales call points other than vascular surgeons; disruptions to our information technology systems or breaches of our information security systems; our implementation of our new enterprise resource planning system; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the occurrence of litigation relating to product liability, employment matters, intellectual property, contract disputes, and other matters; the occurrence of product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; volatility in the price of our common stock; and other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form

10-K, as updated by our subsequent filings with the SEC, which are all available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

CONTACT:

Gregory Manker

Director of Business Development and Investor

Relations ir@LEMAITRE.COM

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Lemaitre Vascular earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.